Mannkind Corp (NASDAQ:MNKD)
| Market Cap | 1.09B-36.7% |
| Revenue (ttm) | 393.63M+30.5% |
| Net Income | -43.61M-233.0% |
| EPS | -0.14-225.7% |
| Shares Out | 319.39M |
| PE Ratio | n/a |
| Forward PE | 1365.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 687,580.054 |
| Open | 3.42 |
| Previous Close | 3.45 |
| Day's Range | 3.41 - 3.53 |
| 52-Week Range | 2.23 - 6.51 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 10.00(+193.01%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MNKD
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MNKD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MNKD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MNKD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MNKD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MNKD Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Product Revenue | $71.58M | 65.45% |
| Royalties | $32.37M | 29.60% |
| Services | $5.42M | 4.96% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MNKD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MNKD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MNKD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $37.40M |
| IWMiShares Russell 2000 ETF | $28.65M |
| XBIState Street SPDR S&P Biotech ETF | $27.85M |
| VXFVanguard Extended Market ETF | $14.36M |
| IWOiShares Russell 2000 Growth ETF | $10.27M |
| IBBiShares Biotechnology ETF | $8.01M |
Estimated from each fund’s disclosed top holdings × AUM
MNKD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MNKD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score